Currency Effects Cause Slight Revenue Dip for Carl Zeiss Meditec in H1 2023/24

• Carl Zeiss Meditec reported a slight decline in revenue for the first six months of fiscal year 2023/24, with revenue of around €947.2m, a decrease of -2.8% compared to the prior year.
• The company's Earnings Before Interest and Taxes (EBIT) also declined to around €108.2m, with an EBIT margin of 11.4%.
• The decline in revenue and EBIT was attributed to currency effects and a planned reduction of stocks of surgical consumables in the Chinese distribution channel.
• The company's Ophthalmology strategic business unit saw a decrease in revenue by -5.7%, while the Microsurgery strategic business unit reported a growth of 6.3%.
• The company saw a significant decrease in revenue in the Americas region by -20.0%, while the EMEA region reported an increase in revenue by +17.1%.
• Carl Zeiss Meditec completed the acquisition of D.O.R.C. in April 2024, which is expected to contribute around €100m in revenue in the second half of 2023/24.

The next important date, Publication of the semi-annual financial report, at Carl Zeiss Meditec is on 08.05.2024.

At this time, the index MDAX was at 26.579,08PKT (-0,25 %).

Carl Zeiss Meditec

-0,39 %

-3,99 %

-11,57 %

-20,21 %

-18,08 %

-41,34 %

+2,18 %

+309,29 %

+781,68 %

ISIN:DE0005313704WKN:531370

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max